The request for the import of 66 million doses of the shot was denied on Monday (26). Anvisa listed a number of issues, among which the alleged presence of adenoviruses capable of replicating in the body of patients who receive the jab.
Representatives from 18 states and the Federal District paid a visit (Mar. 2) to the facilities of pharmaceutical company União Química. The firm is tasked with the production of the active pharmaceutical ingredient (API) for Sputnik V, Russia’s vaccine against COVID-19.
“We’ll strike the deal for 10 million doses and purchase them if the price is acceptable, and we’ll pay after Anvisa grants its authorization for the emergency use of Sputnik V, making it immediately available to Brazilians,” the executive secretary at the Health Ministry said.
Português 
Español 
